Slide 1: Eden Research plc 2017 Interim Results and Update
Eden Research plc 2017 Interim Results and Update 29th September 2017
Slide 2: Contents
Contents ● Introduction & company overview pages 3 - 7 ● Operational highlights page 8 - 9 ● Financial highlights pages 10 - 12 ● Sipcam overview pages 13 - 15 ● 2017 focus page 16 ● Outlook page 17 2
Slide 3: Introduction
Introduction ● Eden is an industrial biotechnology company that delivers Natural Solutions to challenges in plant protection, consumer products and animal health ● Eden’s key markets include biopesticides for high-value crops, conventional pesticides, human and animal health ● There is excellent pot
Slide 4: Board of directors
Board of directors Tom Lupton - Non-Executive Chairman (December 2012) Tom studied Agriculture and Forest Sciences at Oxford University, and spent 23 years working with the Commonwealth Development Corporation developing and managing large agribusiness companies in Southern Africa, culminating in be
Slide 5: Overview
Overview ● Our vision is to be the leader in naturally-derived bioactive products enabled or enhanced by our novel encapsulation and delivery technologies ● Our products are based upon natural chemistries that deliver performance, ease of use, and cost on par with synthetic pesticides ● Our focus is
Slide 6: Biocontrol products
Biocontrol products ● Terpenes have well-documented biocidal activity but are difficult to use commercially due to their inherent volatility ● Using Eden’s Sustaine microencapsulation system, Eden and its partners have been able to create a range of natural products with superior efficacy ● The Sust
Slide 7: Our delivery technology
Our ● Eden owns the patents behind the “Sustaine” delivery technology and release technology ● Sustaine is a natural microencapsulation system enabling the slow release and improved bioavailability of active substances such as terpenes and/or synthetic compounds ● The microcapsules are derived from
Slide 8: 2017 highlights
2017 highlights ● Approval in France for the marketing, sale and use of 3AEY – marketed in France as Mevalone, Yatto and Nirka ● First shipments to France ● Approval in Cyprus and Albiania for the marketing, sale and use of Mevalone – extended label (e.g. Greece) ● Approval in Portugal for the marke
Slide 9: Products on the market
Products on the market —_— —_— — | | — — — THE NATURAL SOLUTION COMMERCIALISATION STATUS OF 3AEY ? Wf © VALONZ MEVALONE
Slide 10: Financial results H1 2017
Financial results H1 2017 ● Revenue of £1.03m (2016: £0.11m) ● Operating Profit for the period increased to £0.21m (H1 2016: loss of £0.86m) ● Profit before tax of £0.2m (H1 2016: loss of £0.86m) ● Profit per share of 0.11p (H1 2016: loss of 0.44p) 10
Slide 11: Financial results H1 2017
Financial results H1 2017 ● Net cash of £3.66m (H1 2016: £2.01m) ● Strategic investment of £2.2m by Sipcam and placing of £0.2m (gross) to institutional investors ● Expanding investment in regulatory clearances unlocking commercial potential in new, important territories ● Current trading is in line
Slide 12: H1 2017 income statement
H1 2017 income statement — — — | ) — — — THE NATURAL SOLUTION Revenue Cost of sales Gross profit Administrative expenses Exceptional royalties refund Amortisation of intangible assets Share based payments Total other operating expenses Operating profit/(loss) Finance income/(costs) Share of loss of
Slide 13: Sipcam strategic investment summary
Sipcam ● Strategic investment summary ● Sipcam has proven itself as a good partner in Italy and Spain ● Sipcam is a valued formulator, partner and supplier to nearly all of the industry leaders ● The three year lock-in indicates that Sipcam intends to be a longer term partner with a vested interest
Slide 14: Sipcam overview
Sipcam overview Sipcam was founded in 1946 in Milan, by Dr. Emilio Gagliardini and Prof. Baldo Ciocca as a company specialized in manufacturing and marketing of agrochemicals for agriculture in Italy 14
Slide 15: Sipcam overview
— — ——— sd — — THE NATURAL SOLUTION Distribution Network tribution Sumi Agro LTD # |o SIPCAM | 1A: Growing attitude 15
Slide 16: 2017 focus
● Nematicide deal execution 2017 focus ● Sipcam deal execution ● Further partnerships for 3AEY in key new territories ● Re-initiation of screening and field trials ● Pursue opportunities in the $4.2B seed treatments market ● Accelerate commercialisation of Sustaine ● Regulatory strategy and expansio
Slide 17: Outlook
Outlook ● Based on these interim results, and the significant commercial and regulatory progress made over the last six months, current trading is in line with the Board’s expectations for the full year. ● The Company is well-placed to continue its growth and to leverage its new and existing relatio
Slide 18: Disclaimer
• The content of information contained in these slides and the accompanying verbal presentation (together, the “Presentation”) has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”). Reliance upon this Presentation for the purpose of
Slide 19: Eden Research plc contact details
Eden Research plc 6 Priory Court Priory Court Business Park Poulton, Cirencester GL7 5JB